Description

AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)—-C115H187N33O42—-[1]Andrea Valentine, et al. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res. 2011 Mar 1;17(5):1044-56.|[2]Anita Yakkundi, et al. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One. 2013;8(2):e55075.–959961-23-0–2703.94–97.03–O=C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(N3[C@@H](CCC3)C(N[C@@H](C)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]4N(CCC4)C([C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H]5N(CCC5)C([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@@H](N)CCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–H2O : 12.5 mg/mL (ultrasonic)–Others—-Others–Peptides